Oyster Point Pharma Drug Patent Portfolio

Oyster Point Pharma owns 1 orange book drug protected by 10 US patents Given below is the list of Oyster Point Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10456396 Dry eye treatments 19 Oct, 2035
Active
US11224598 Methods of increasing lacrimal proteins 19 Oct, 2035
Active
US11903941 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
Active
US11903942 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
Active
US11903943 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
Active
US11911380 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
Active
US9504644 Methods of increasing tear production 19 Oct, 2035
Active
US9504645 Pharmaceutical formulations for treating ocular conditions 19 Oct, 2035
Active
US9532944 Methods of improving ocular discomfort 19 Oct, 2035
Active
US9597284 Dry eye treatments 19 Oct, 2035
Active


Given below is the list of recent legal activities going on the following drug patents of Oyster Point Pharma.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 25 Jun, 2024 US9532944
Patent eCofC Notification 04 Jun, 2024 US11903942
Recordation of Patent eCertificate of Correction 04 Jun, 2024 US11903942
Mail Patent eCofC Notification 04 Jun, 2024 US11903942
Email Notification 04 Jun, 2024 US11903942
Payment of Maintenance Fee, 8th Year, Large Entity 21 May, 2024 US9504645
Payment of Maintenance Fee, 8th Year, Large Entity 21 May, 2024 US9504644
Post Issue Communication - Certificate of Correction 15 May, 2024 US11903942
Recordation of Patent eGrant 27 Feb, 2024 US11911380
Recordation of Patent Grant Mailed 27 Feb, 2024 US11911380
Mail Patent eGrant Notification 27 Feb, 2024 US11911380
Email Notification 27 Feb, 2024 US11911380
Patent eGrant Notification 27 Feb, 2024 US11911380
Patent Issue Date Used in PTA Calculation 27 Feb, 2024 US11911380
Recordation of Patent eGrant 20 Feb, 2024 US11903942


Oyster Point Pharma Drug Patents' Oppositions Filed in EPO

Oyster Point Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 09, 2021, by Beck Greener Llp. This opposition was filed on patent number EP15852340A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP15852340A Sep, 2021 Beck Greener LLP Granted and Under Opposition


Oyster Point Pharma's Family Patents

Oyster Point Pharma drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 28.6% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Oyster Point Pharma Drug List

Given below is the complete list of Oyster Point Pharma's drugs and the patents protecting them.


1. Tyrvaya

Tyrvaya is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10456396 Dry eye treatments 19 Oct, 2035
(11 years from now)
Active
US11224598 Methods of increasing lacrimal proteins 19 Oct, 2035
(11 years from now)
Active
US11903941 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
(11 years from now)
Active
US11903942 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
(11 years from now)
Active
US11903943 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
(11 years from now)
Active
US11911380 Compositions and use of varenicline for treating dry eye 19 Oct, 2035
(11 years from now)
Active
US9504644 Methods of increasing tear production 19 Oct, 2035
(11 years from now)
Active
US9504645 Pharmaceutical formulations for treating ocular conditions 19 Oct, 2035
(11 years from now)
Active
US9532944 Methods of improving ocular discomfort 19 Oct, 2035
(11 years from now)
Active
US9597284 Dry eye treatments 19 Oct, 2035
(11 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tyrvaya's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List